Table 1.
Baseline characteristics of subjects
| Placebo (n = 6) | Sitagliptin (n = 6) | |
| Demographics | ||
| Age (yr) | 54.7 ± 9.8 | 56.7 ± 9.9 |
| Gender - male, n (%) | 2 (33) | 3 (50) |
| White, n (% | 6 (100 | 5 (83) |
| Weight (kg) | 105.8 ± 23.5 | 100.4 ± 28.7 |
| BMI (kg/m2) | 37.4 ± 4.7 | 35.9 ± 6.6 |
| Diabetes duration (yr)1 | 6.0 (5.0, 6.0) | 6.5 (5.0, 23.0) |
| NASH Duration (yr)1 | 4.0 (1.0, 4.0) | 1.3 (0.1, 2.0) |
| Biochemical profile | ||
| HbA1C (%) | 8.2 ± 0.9 | 7.9 ± 1.0 |
| HOMA-IR | 3.5 ± 2.2 | 3.4 ± 1.2 |
| Fasting glucose (mmol/L) | 11.3 ± 4.9 | 8.1 ± 3.1 |
| Fasting insulin (pmol/L) | 165 ± 134 | 168 ± 63 |
| AST (IU/L) | 39 ± 19 | 44 ± 22 |
| ALT (IU/L) | 46 ± 36 | 72 ± 50 |
| Alkaline phosphatase (IU/L) | 85 ± 34 | 93 ± 41 |
| GGT (IU/L) | 100 ± 98 | 164 ± 182 |
| Triglycerides (mmol/L) | 2.33 ± 2.00 | 2.80 ± 1.64 |
| HDL-C (mmol/L) | 1.10 ± 0.34 | 1.12 ± 0.46 |
| LDL-C (mmol/L) | 1.61 ± 0.71 | 1.42 ± 0.97 |
| Free fatty acids (μmol/L) | 645 ± 195 | 559 ± 158 |
| Platelet aggregation (PRU) | 292 ± 37 | 236 ± 28 |
| Histologic profile | ||
| Fibrosis | 2.2 ± 0.8 | 2.2 ± 1.0 |
| NAS | 4.2 ± 1.5 | 3.8 ± 0.8 |
| Steatosis | 1.8 ± 0.8 | 1.8 ± 0.8 |
| Lobular Inflammation | 1.2 ± 0.4 | 1.0 ± 0 |
| Ballooning | 1.2 ± 0.4 | 1.0 ± 0 |
| MRI | ||
| Hepatic fat (%) | 21.9 ± 10.6 | 19.0 ± 9.7 |
| SAAT (%) | 40.5 ± 7.1 | 38.0 ± 22.0 |
| VAT (%) | 30.5 ± 3.4 | 26.8 ± 11.6 |
| Left thigh fat (%) | 37.8 ± 9.9 | 39.5 ± 15.8 |
1
Data are presented as median (Q1, Q3). Data are presented as mean ± SD, unless otherwise specified. ALT: Alanine aminotransferase; AST: Aspartate transferase; BMI: Body mass index; HbA1C: Hemoglobin A1C; HOMA-IR: Homeostasis model of assessment for insulin resistance; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; NAS: Non-alcoholic fatty liver disease activity score; NASH: Non-alcoholic steatohepatitis; MRI: Magnetic resonance imaging; PRU: Platelet reaction units; SAAT: Subcutaneous abdominal adipose tissue; VAT: Visceral adipose tissue.